Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index; 7 of the 44 sources its claims cite were checked for support.

Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation

Open access

Abstract

Mutations in the KRAS gene have long been implicated in the pathogenesis of colorectal cancer (CRC). KRAS G12C inhibitors overcome the “undruggable” challenge, enabling precision therapy. Garsorasib (D-1553), a highly potent and selective KRAS G12C inhibitor, has demonstrated promising anti-tumor activity and favorable safety profile in early clinical trials. We conducted an open-label, nonrandomized phase II trial (ClinicalTrials.gov, NCT04585035) to assess the safety and efficacy of garsorasib with or without cetuximab in KRAS G12C-mutated CRC. In the monotherapy cohort (n = 26), objective response rate (ORR) was 19.2% (95% CI, 6.6–39.4), disease control rate (DCR) was 92.3% (95% CI, 74.9–99.1), median progression-free survival (PFS) was 5.5 months (95% CI, 2.9–11.6) and median overall survival (OS) was 13.1 months (95% CI, 9.5-NE). In the combination cohort (n = 42), ORR was 45.2% (95% CI, 29.8–61.3), DCR was 92.9% (95% CI, 80.5–98.5), median PFS was 7.5 months (95% CI, 5.5–8.1), and median OS was not reached. Grade ≥3 treatment-related adverse events occurred in 5 (19.2%) and 6 (14.3%) patients in monotherapy and combination cohort, respectively. Garsorasib with or without cetuximab showed a promising efficacy and manageable safety profiles in heavily pretreated patients with KRAS G12C-mutated CRC, providing a potential new treatment approach for such population.

Overview

CoChat Summary

TL;DR

In pretreated KRAS G12C-mutated metastatic colorectal cancer, garsorasib plus cetuximab produced higher response rates and longer progression-free survival than garsorasib monotherapy, with manageable toxicity in both cohorts. The trial was open-label and nonrandomized, so the combination’s apparent advantage requires confirmation in larger randomized studies.

Key findings

  • In the monotherapy cohort (n = 26), confirmed ORR was 19.2% (95% CI, 6.6–39.4), DCR was 92.3% (95% CI, 74.9–99.1), median PFS was 5.5 months (95% CI, 2.9–11.6), and median OS was 13.1 months (95% CI, 9.5–NE).
  • In the combination cohort (n = 42), confirmed ORR was 45.2% (95% CI, 29.8–61.3), DCR was 92.9% (95% CI, 80.5–98.5), median PFS was 7.5 months (95% CI, 5.5–8.1), and median OS was not reached (95% CI, 11.3–NE).
  • Grade ≥3 treatment-related adverse events occurred in 5 (19.2%) patients with monotherapy and 6 (14.3%) patients with combination therapy; no fatal TRAEs were reported.
  • The most common TRAEs in the combination cohort were skin/subcutaneous tissue disorders and liver function abnormalities, while monotherapy TRAEs were most commonly liver function abnormalities and gastrointestinal events.

Methods

  • Open-label, nonrandomized phase II study within a multicenter phase I/II trial (NCT04585035); CRC cohorts included patients with pretreated advanced or metastatic KRAS G12C-mutated CRC.
  • Monotherapy cohort: 26 patients from Arm B received oral garsorasib 600 mg twice daily. Combination cohort: 42 patients from Arm F received garsorasib 600 mg twice daily plus intravenous cetuximab 400 mg/m² on day 1 of cycle 1 and 250 mg/m² weekly thereafter.
  • Primary endpoint was ORR by investigator per RECIST v1.1; secondary endpoints included DCR, PFS, DOR, OS, and adverse events. Efficacy analyses followed the ITT principle; ORR/DCR used Clopper-Pearson 95% CIs, and PFS/OS/DOR used Kaplan-Meier methods.

Limitations

  • The paper states the nonrandomized design does not allow direct comparisons between garsorasib monotherapy/combination and standard-of-care.
  • The paper states the sample size was relatively small and randomized trials with larger sample sizes are needed.
  • The paper states follow-up was not long enough to capture the long-term survival benefit of the combination cohort; the text also notes no formal statistical hypothesis was prespecified.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41392-025-02274-z

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Image 1
CC-BY · From the PDF
Fig. 2 Ef fi cacy outcomes with garsorasib monotherapy. a Best tumor response and tumor burden change from baseline. b Swimmer plot of time to response, treatment duration. c Kaplan-Meier estimates of progression-free survival
Fig. 2 Ef fi cacy outcomes with garsorasib monotherapy. a Best tumor response and tumor burden change from baseline. b Swimmer plot of time to response, treatment duration. c Kaplan-Meier estimates of progression-free survivalCC-BY · From the PDF
Fig. 3 Ef fi cacy outcomes with garsorasib plus cetuximab. a Best tumor response and tumor burden change from baseline. b Swimmer plot of time to response, treatment duration. c Kaplan-Meier estimates of progression-free survival
Fig. 3 Ef fi cacy outcomes with garsorasib plus cetuximab. a Best tumor response and tumor burden change from baseline. b Swimmer plot of time to response, treatment duration. c Kaplan-Meier estimates of progression-free survivalCC-BY · From the PDF

Verification

Claims the paper makes

4 Valid · 1 Not valid · 25 Not checked · 75 Own results and interpretations

64 more claims

Create a free account to see all 105 claims and to verify the 37 references still open.

See all claims — free account
  • It may state two separate claims as one. 25
  • The quote only partly states this claim. 4
  • Probably not a substantial claim. 9

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

1 of 1

Citations

Cites

Show all 32 references

Metadata

Authors
Ruan, D.-Y., Wu, H.-X., Xu, Y., Munster, P. N., Deng, Y., Richardson, G., Yan, D., Lee, M.-A., Lee, K.-W., Pan, H., Hager, S., Li, X., Wei, S., Hou, X., Underhill, C., Millward, M., Nordman, I., Zhang, J., Shan, J., Han, G., Grewal, J., Gadgeel, S. M., Sanborn, R. E., Huh, S. J., Hu, X., Zhang, Y., Xiang, Z., Luo, L., Xie, X., Shi, Z., Wang, Y., Zhang, L., Wang, F., & Xu, R.-H.
Affiliations
  • Sun Yat-sen University (CN)
  • Fudan University (CN)
  • Cabrini Hospital (AU)
  • The Catholic University of Korea Seoul St. Mary's Hospital (KR)
  • Seoul National University (KR)
  • Sir Run Run Shaw Hospital (CN)
  • California Cancer Associates for Research and Excellence (US)
  • First Affiliated Hospital of Zhengzhou University (CN)
  • Hubei Cancer Hospital (CN)
  • Henan Cancer Hospital (CN)
  • Albury Wodonga Health (AU)
  • The University of Western Australia (AU)
  • Calvary Mater Newcastle Hospital (AU)
  • Liaoning Cancer Hospital & Institute (CN)
  • First Affiliated Hospital Zhejiang University (CN)
  • Henry Ford Health (US)
  • Dong-A University Hospital (KR)
  • First Affiliated Hospital of GuangXi Medical University (CN)
  • InventisBio Co., Ltd. (China) (CN)
Corresponding author
  • Wang, Feng
  • Xu, Rui-Hua
Venue
Signal Transduction and Targeted Therapy
Published
2025-06-17
Volume
10
Issue
1
Pages
189-189
ISSN
2059-3635 (ISSN-L)
OpenAlex
W4411331277
Cited by
22
References
32
Citations by year
2026: 16 · 2025: 6
FWCI
9.11
Type
journal article
Language
en
Open access
Licence
Locations
  • Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • UWA Profiles and Research Repository (UWA) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords
KRAS G12C inhibitors, cetuximab, anti-EGFR monoclonal antibody, colorectal cancer, KRAS G12C mutation, combination therapy, monotherapy, advanced solid tumors, treatment-related adverse events, progression-free survival, objective response rate
MeSH terms
Cetuximab, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Male, Middle Aged, Mutation, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation. https://app.cochat.ai/papers/10.1038/s41392-025-02274-z
The paper
Ruan, D.-Y., Wu, H.-X., Xu, Y., Munster, P. N., Deng, Y., Richardson, G., Yan, D., Lee, M.-A., Lee, K.-W., Pan, H., Hager, S., Li, X., Wei, S., Hou, X., Underhill, C., Millward, M., Nordman, I., Zhang, J., Shan, J., . . . Xu, R.-H. (2025). Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation. Signal Transduction and Targeted Therapy. https://doi.org/10.1038/s41392-025-02274-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.